Fox Chase Cancer Center and Oryzon Genomics S.A. formed a collaboration to test the safety and efficacy of the drug iadademstat in patients with pulmonary and extrapulmonary neuroendocrine carcinomas, which are rare and heterogeneous cancers arising from neuroendocrine cells, and small cell lung cancer.
Sarah Bigelow was named executive director of the Clinical Trials Office at the Tulane Cancer Center.
